Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
Degirmenci U, Wang M, Hu J. · 2020
Read Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. by Degirmenci U, Wang M, Hu J. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7017232.txt.
Description
Degirmenci, Wang, and Hu review a key cancer signalling pathway in the journal Cells. The RAS/RAF/MEK/ERK cascade carries signals that control cell growth, survival, and differentiation. Mutations in its genes drive about one-third of human cancers. Blocking the pathway is therefore a major goal of cancer drug design.
The review traces the cascade from its discovery to recent work on RAF control. RAF activity turns on shape changes, self-blocking, pairing, and phosphate tags. A central problem is paradoxical activation, where a RAF-blocking drug can switch the pathway on instead. The authors weigh what this means for treatment. They focus on how new findings could yield drugs that shut the pathway down without that rebound.
Catalog record
| CREATOR | Degirmenci U, Wang M, Hu J. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 121 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |